KMT Hepatech is a preclinical development contractor for the NIH / NIAID
Since 2006 KMT Hepatech has been the only preclinical development contractor worldwide for the US National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) to provide in vivo testing of antiviral agents for hepatitis B (HBV) and hepatitis C (HCV)*. NIH / NIAID provides access to the SCID-Alb-uPA chimera mouse model engrafted with human hepatocytes to academic and (bio)pharmaceutical company sponsors free of charge.
Potential clients may contact NIH directly or inquire about this opportunity at KMT Hepatech.
*- This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201700021